p53 and MYC-regulated squalene epoxidase as Achilles heel in colorectal cancer

被引：0
|
作者：
Fischer, Martin [1 ]
机构：
[1] Fritz Lipmann Inst FLI, Leibniz Inst Aging, Computat Biol Grp, Beutenbergstr 11, D-07745 Jena, Germany
来源：
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES | 2023年 / 19卷 / 15期
关键词：
tumor suppressor p53; transcription factor MYC; SQLE; cholesterol synthesis; Terbinafine; colorectal cancer;
D O I：
10.7150/ijbs.89237
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The transcription factors p53 and MYC are often considered non-druggable targets, but their dysregulation can generate new dependencies and treatment opportunities in cancer cells. The p53 and MYC-regulated squalene epoxidase (SQLE) has been identified as a potential Achilles heel in colorectal cancer. This is of great interest because the FDA-approved anti-fungal SQLE inhibitor Terbinafine could be repurposed to treat colorectal cancer patients.
引用
收藏
页码：4831 / 4832
页数：2
相关论文
共 50 条
  • [41] Tyrosine expression is regulated by p53
    Khlgatian, M
    Asawanonda, P
    Eller, M
    Yaar, M
    Fujita, M
    Norris, DA
    Gilchrest, BA
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1999, 112 (04) : 548 - 548
  • [42] Expression of circZNF609 is Down-Regulated in Colorectal Cancer Tissue and Promotes Apoptosis in Colorectal Cancer Cells by Upregulating p53
    Zhang, Xiaoyun
    Zhao, Yalei
    Kong, Peng
    Han, Mei
    Li, Binghui
    MEDICAL SCIENCE MONITOR, 2019, 25 : 5977 - 5985
  • [43] Immunohistochemical analysis of P53 and MAF expression in colorectal cancer
    Toyama, Chika
    Takeda, Koki
    Yokoyama, Yuhki
    Iso, Kenji
    Hata, Tsuyoshi
    Haraguchi, Naotsugu
    Nishida, Naohiro
    Hata, Taishi
    Matsuda, Chu
    Mizushima, Tsunekazu
    Doki, Yuichiro
    Mori, Masaki
    Yamamoto, Hirofumi
    CANCER SCIENCE, 2018, 109 : 836 - 836
  • [44] Mismatch repair, p53 and β-catenin proteins in colorectal cancer
    Valentini, AM
    Renna, L
    Armentano, R
    Pirrelli, M
    Di Leo, A
    Gentile, M
    Caruso, ML
    ANTICANCER RESEARCH, 2002, 22 (04) : 2083 - 2088
  • [45] The correlation of p53 and egfr with prognosis factor on colorectal cancer
    Lee, J.
    Kang, B. Y.
    Roh, N. G.
    Chung, S. S.
    Kim, K. H.
    Park, E. B.
    Lee, R. A.
    ANNALS OF ONCOLOGY, 2007, 18 : VII41 - VII41
  • [46] Prediagnostic Antibodies to Serum p53 and Subsequent Colorectal Cancer
    Teras, Lauren R.
    Gapstur, Susan M.
    Maliniak, Maret L.
    Jacobs, Eric J.
    Gansler, Ted
    Michel, Angelika
    Pawlita, Michael
    Waterboer, Tim
    Campbell, Peter T.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2018, 27 (02) : 219 - 223
  • [47] Alteration of p53 clonality accompanying colorectal cancer progression
    Kuwabara, K
    Watanabe, H
    Ajioka, Y
    Yasuda, K
    Saito, H
    Matsuda, K
    Kijima, H
    Hatakeyama, K
    JAPANESE JOURNAL OF CANCER RESEARCH, 1998, 89 (01): : 40 - 46
  • [48] P53 abnormalities and outcomes in colorectal cancer: a systematic review
    A J Munro
    S Lain
    D P Lane
    British Journal of Cancer, 2005, 92 : 434 - 444
  • [49] P53 abnormalities and outcomes in colorectal cancer: a systematic review
    Smith, FM
    Stephens, RB
    Kennedy, MJ
    Reynolds, JV
    BRITISH JOURNAL OF CANCER, 2005, 92 (09) : 1813 - 1813
  • [50] P53 and beta-catenin in colorectal cancer progression
    Valentini, AM
    Pirrelli, M
    Renna, L
    Armentano, R
    Caruso, ML
    CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (24) : 1932 - 1936
12345